Publications by authors named "Valery V Shipitsyn"
Article Synopsis
- Diazepam is commonly used to treat alcohol withdrawal syndrome, but some patients may not respond well or experience adverse reactions due to its metabolism involving variable enzymes (CYP3A4 and CYP3A5).
- The study evaluated 100 male patients receiving diazepam for 5 days, focusing on two specific genetic polymorphisms and their effects on efficacy and safety.
- Findings indicated that certain genetic variants increased the risk of adverse drug reactions and reduced the safety of diazepam therapy, suggesting that genetic testing could help optimize treatment for alcohol withdrawal.
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
J Psychiatr Pract
September 2021
Introduction: Fluoxetine is used in the treatment of patients with recurrent depressive disorder. Some of these patients do not achieve an adequate response to a treatment regimen containing fluoxetine, and many of these patients experience dose-dependent adverse drug reactions. The cytochrome P450 enzyme CYP2D6 is involved in the biotransformation of fluoxetine, the activity of which is quite dependent on the polymorphism of the gene encoding this enzyme.
View Article and Find Full Text PDFBackground: Diazepam is one of the most commonly prescribed tranquilizers for the therapy of alcohol withdrawal syndrome (AWS). Despite its popularity, there is currently no precise information on the effect of genetic polymorphisms on the efficacy and safety of diazepam therapy.
Objective: The objective of our study was to study the effect of CYP3A isoenzymes activity on the efficacy and safety of diazepam in patients with AWS.
Background Diazepam is one of the most commonly prescribed tranquilizers for therapy of alcohol withdrawal syndrome (AWS). Despite its popularity, there is currently no precise information on the effect of genetic polymorphisms on its efficacy and safety. The objective of our study was to investigate the effect of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy and safety of diazepam in patients with AWS.
View Article and Find Full Text PDF